Bellicum Pharmaceuticals (NASDAQ: BLCM)
Some price data may be temporarily unavailable.
Bellicum Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Bellicum Pharmaceuticals Company Info
Bellicum Pharmaceuticals, Inc.
News & Analysis
Here's Why Bellicum Pharmaceuticals Lost 13.8% in July
The clinical-stage biopharma just can't catch a break from Wall Street.
Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.
Which stock wins in a battle between these two clinical-stage biotechs with regulatory approvals potentially just around the corner?
Here's Why Bellicum Pharmaceuticals Is Jumping Higher Today
The biopharma announced first-quarter 2018 results and provided an update on the business.
Is Bellicum Pharmaceuticals, Inc. a Buy?
Bellicum Pharmaceuticals may appear like a bargain, but a deeper dive suggests otherwise.
Here's Why Bellicum Pharmaceuticals Dropped as Much as 14.6% Today
The biopharma announced a public offering of common stock.
Is Bellicum Pharmaceuticals Stock Now a Strong Buy?
Bellicum Pharmaceuticals' lead product candidate is back on track. Should investors buy this news?
Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio
Bellicum and bluebird bio are both developing next generation gene therapies, but only one company is a clear cut buy.
Is Bellicum Pharmaceuticals, Inc. a Buy Now?
Enthusiasm for this biotech is at an all-time low. Has the market pushed the stock into bargain territory?
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.